Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment
09 Marzo 2020 - 6:13AM
Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company,
today announced that the Israel Patent Office granted a new patent
(#239236) covering ALLOCETRATM, the company’s immunotherapy
candidate. This new patent adds intellectual property protection,
including methods, uses and pharmaceutical compositions in Israel.
ALLOCETRATM is an experimental therapy being investigated for
treatment of organ dysfunction and prevention of mortality
associated with sepsis, and may potentially be an effective
treatment to restore organ function and prevent mortality of
coronavirus (COVID-19) patients that are admitted to the ICU.
ABOUT ENLIVEX
Enlivex is a clinical stage immunotherapy
company, developing an allogeneic drug pipeline for immune system
rebalancing. Immune system rebalancing is critical for the
treatment of life-threatening immune and inflammatory conditions
which involve an out of control immune system (e.g. Cytokine
Release Syndrome) and for which there are no approved treatments
(unmet medical needs), as well as solid tumors immune-checkpoint
rebalancing. For more information, visitwww.enlivex.com.
Safe Harbor Statement: This
press release contains forward-looking statements, which may be
identified by words such as “expects,” “plans,” “projects,” “will,”
“may,” “anticipates,” “believes,” “should,” “would”, “intends,”
“estimates,” “suggests,” “has the potential to” and other words of
similar meaning, including statements regarding the results of
current clinical studies and preclinical experiments and the
effectiveness of ALLOCETRATM programs, which are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that forward-looking
statements involve risks and uncertainties that may affect
Enlivex’s business and prospects, including the risks that Enlivex
may not succeed in generating any revenues or developing any
commercial products; that the products in development may fail, may
not achieve the expected results or effectiveness and/or may not
generate data that would support the approval or marketing of these
products for the indications being studied or for other
indications; that ongoing studies may not continue to show
substantial or any activity; and other risks and uncertainties that
may cause results to differ materially from those set forth in the
forward-looking statements. The results of clinical trials in
humans may produce results that differ significantly from the
results of clinical and other trials in animals. The results of
early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products
using the ALLOCETRATM product line could also be affected by a
number of other factors, including unexpected safety, efficacy or
manufacturing issues, additional time requirements for data
analyses and decision making, the impact of pharmaceutical industry
regulation, the impact of competitive products and pricing and the
impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors described
above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in
Enlivex’s filings with the Securities and Exchange Commission. The
forward-looking statements contained in this press release speak
only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements,
except as required under applicable law.
ENLIVEX CONTACT:
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd. shachar@enlivexpharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024